ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,05
0,98%
Dow Jones
38 671,52
1,17%
DAX
18 042,90
0,77%
Brent Oil
83,465
-0,20%
Bitcoin
61 709,15
4,38%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Regulus Therapeutics Inc (RGLS)

  7. Regulus Therapeutics Inc (RGLS) Actualités

RGLS Regulus Therapeutics Inc

2,71
0,02 (0,74%)
Dernière mise à jour : 15:55:53
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Regulus Therapeutics Inc RGLS NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,02 0,74% 2,71 15:55:53
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
2,83 2,67 2,83 2,69
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
30/4/202414:00PRNUSRegulus Therapeutics to Participate in the Canaccord Genuity..
21/3/202421:05PRNUSRegulus Therapeutics Reports Fourth Quarter and Year-End..
12/3/202411:32PRNUSRegulus Therapeutics Announces Oversubscribed $100 Million..
12/3/202411:30PRNUSRegulus Therapeutics Announces Positive Topline Data from..
19/1/202402:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/1/202402:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/1/202423:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/1/202423:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/1/202422:11EDGAR2Form S-8 - Securities to be offered to employees in employee..
10/1/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
02/1/202422:05PRNUSRegulus Therapeutics Announces Completion of Enrollment in..
27/12/202322:16EDGAR2Form S-3 - Registration statement under Securities Act of..
22/11/202314:00PRNUSRegulus Therapeutics to Present at the 6th Annual Evercore..
09/11/202322:39EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202322:15EDGAR2Form 8-K - Current report
09/11/202322:05PRNUSRegulus Therapeutics Reports Third Quarter 2023 Financial..
02/11/202313:00PRNUSRegulus Therapeutics Announces First Patient Dosed in Third..
19/10/202314:00PRNUSRegulus Therapeutics Advances to Cohort 3 of Phase 1b..
20/9/202313:00PRNUSRegulus Therapeutics Announces Positive Topline Data from..
13/9/202314:00PRNUSRegulus Therapeutics Announces Completion of Enrollment in..
05/9/202314:00PRNUSRegulus Therapeutics Announces Participation at Two..
23/8/202314:00PRNUSRegulus Therapeutics to Host Virtual Investor Event on..
14/8/202322:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202322:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202322:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202322:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202322:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202322:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/8/202322:46EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202322:15EDGAR2Form 8-K - Current report
08/8/202322:05PRNUSRegulus Therapeutics Reports Second Quarter 2023 Financial..
02/8/202314:00PRNUSRegulus Therapeutics to Present at the Canaccord Genuity..
18/7/202314:00PRNUSRegulus Therapeutics to Present at the H.C. Wainwright 2nd..
29/6/202322:53EDGAR2Form S-8 - Securities to be offered to employees in employee..
27/6/202314:00PRNUSRegulus Therapeutics Announces First Patient Dosed in Second..
23/6/202314:00PRNUSRegulus Therapeutics Announces Appointment of Preston S...
20/6/202314:00PRNUSRegulus Therapeutics Announces Update on Preclinical Studies..
12/6/202314:00PRNUSRegulus Therapeutics Strengthens Research & Development..
16/5/202314:00PRNUSRegulus Therapeutics Advances to Cohort 2 of Phase 1b..
11/5/202322:05PRNUSRegulus Therapeutics Reports First Quarter 2023 Financial..

Dernières Valeurs Consultées

NASDAQ
RGLS
Regulus Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés